Related Experiment Video
Updated: Jul 19, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Oral renin inhibitors.
Jan A Staessen1, Yan Li, Tom Richart
1Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium. jan.staessen@med.kuleuven.be
Lancet (London, England)
|October 24, 2006
Summary
Renin inhibitors block the renin-angiotensin system to treat cardiovascular and renal disorders. Aliskiren, a new oral renin inhibitor, shows promise for hypertension and related conditions.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- The renin-angiotensin system plays a key role in cardiovascular and renal disorders.
- Inhibiting renin, the system's origin, has been a therapeutic goal for over 30 years.
- Previous oral renin inhibitors lacked clinical efficacy due to poor bioavailability and activity.
Purpose of the Study:
- To review the development of oral renin inhibitors.
- To summarize the pharmacokinetic and pharmacodynamic properties of these agents.
- To focus on aliskiren, the first non-peptide renin inhibitor in phase-III trials.
Main Methods:
- Review of preclinical and clinical data on oral renin inhibitors.
- Analysis of pharmacokinetic and pharmacodynamic profiles.
- Focus on aliskiren's progression in clinical trials.
Main Results:
- Aliskiren is the first orally active, non-peptide renin inhibitor to reach phase-III clinical trials.
- It demonstrates potential for treating hypertension and associated cardiovascular and renal disorders.
- New compounds with enhanced properties are under preclinical investigation.
Conclusions:
- Oral renin inhibitors represent a significant advancement in managing renin-angiotensin system-mediated diseases.
- Aliskiren is a leading candidate for clinical use in hypertension and related conditions.
- Ongoing research aims to develop improved oral renin inhibitors with better bioavailability and efficacy.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...